Exton, PA ; 03/27/2020
Amount Funded: $75 Million ($55 million from equity investors)
Type: Not Listed
Lead Investor: Paragon Biosciences (owner of Castle Creek Biosciences)
Participating Investor(s): Fidelity Management & Research Company, Valor Equity Partners. Horizon Technology Finance Corp. loaned $20 million in venture funds.
Company Description: Castle Creek Biosciences is a privately held company that develops and commercializes gene therapies for patients with rare and serious genetic diseases. The company’s lead gene therapy candidate, FCX-007, is being evaluated for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), the most severe and debilitating form of epidermolysis bullosa (EB). The company is also advancing clinical research evaluating a diacerein topical ointment, CCP-020, for the treatment of epidermolysis bullosa simplex (EBS) and other forms of EB. In addition, Castle Creek Biosciences is developing FCX-013, a gene therapy for the treatment of moderate to severe localized scleroderma.
What funding will be used for: Expand, advance gene therapy candidate for RDEB treatment, expand infrastructure in greater Philadelphia.
“We are proud to have the strategic support of world-class investors whose impact enables our efforts to transform the lives of patients and the future of medicine.”
-John Maslowski, CEO, Castle Creek Biosciences
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.